JP2015521471A - 組み換え第Xa因子誘導体の精製のための方法 - Google Patents
組み換え第Xa因子誘導体の精製のための方法 Download PDFInfo
- Publication number
- JP2015521471A JP2015521471A JP2015517406A JP2015517406A JP2015521471A JP 2015521471 A JP2015521471 A JP 2015521471A JP 2015517406 A JP2015517406 A JP 2015517406A JP 2015517406 A JP2015517406 A JP 2015517406A JP 2015521471 A JP2015521471 A JP 2015521471A
- Authority
- JP
- Japan
- Prior art keywords
- elution buffer
- serine protease
- sti
- arginine
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000000746 purification Methods 0.000 title claims description 23
- 108010074860 Factor Xa Proteins 0.000 title description 13
- 239000012149 elution buffer Substances 0.000 claims abstract description 56
- 102000012479 Serine Proteases Human genes 0.000 claims abstract description 53
- 108010022999 Serine Proteases Proteins 0.000 claims abstract description 53
- 239000002753 trypsin inhibitor Substances 0.000 claims abstract description 15
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 229940122618 Trypsin inhibitor Drugs 0.000 claims abstract description 13
- 101710162629 Trypsin inhibitor Proteins 0.000 claims abstract description 13
- 244000068988 Glycine max Species 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 230000003993 interaction Effects 0.000 claims abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 239000004475 Arginine Substances 0.000 claims description 37
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical group NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 239000003112 inhibitor Substances 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 22
- 150000001413 amino acids Chemical group 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 14
- 239000011534 wash buffer Substances 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 239000000816 peptidomimetic Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 7
- 230000003196 chaotropic effect Effects 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 claims description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims 1
- 108010018682 PRT064445 Proteins 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 43
- 239000011347 resin Substances 0.000 description 33
- 229920005989 resin Polymers 0.000 description 33
- 229920000936 Agarose Polymers 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 229920002684 Sepharose Polymers 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 239000000729 antidote Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 230000002947 procoagulating effect Effects 0.000 description 9
- -1 DNA or RNA Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 108010014806 prothrombinase complex Proteins 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 229940075522 antidotes Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960001148 rivaroxaban Drugs 0.000 description 3
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 2
- NPBKHEMDWREFJJ-UHFFFAOYSA-N 2-[(7-carbamimidoylnaphthalen-2-yl)methyl-[4-(1-ethanimidoylpiperidin-4-yl)oxyphenyl]sulfamoyl]acetic acid Chemical compound C1CN(C(=N)C)CCC1OC1=CC=C(N(CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)S(=O)(=O)CC(O)=O)C=C1 NPBKHEMDWREFJJ-UHFFFAOYSA-N 0.000 description 2
- 101800001401 Activation peptide Proteins 0.000 description 2
- 102400000069 Activation peptide Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 229960003886 apixaban Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229950011103 betrixaban Drugs 0.000 description 2
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 108090001015 cancer procoagulant Proteins 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- IJNIQYINMSGIPS-UHFFFAOYSA-N darexaban Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC(O)=C1NC(=O)C1=CC=C(N2CCN(C)CCC2)C=C1 IJNIQYINMSGIPS-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 229960000622 edoxaban Drugs 0.000 description 2
- QQBKAVAGLMGMHI-WIYYLYMNSA-N eribaxaban Chemical compound N1([C@H](C[C@H](C1)OC)C(=O)NC=1C(=CC(=CC=1)N1C(C=CC=C1)=O)F)C(=O)NC1=CC=C(Cl)C=C1 QQBKAVAGLMGMHI-WIYYLYMNSA-N 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GEHAEMCVKDPMKO-HXUWFJFHSA-N 1-[1-[(2s)-3-(6-chloronaphthalen-2-yl)sulfonyl-2-hydroxypropanoyl]piperidin-4-yl]-1,3-diazinan-2-one Chemical compound O=C([C@@H](CS(=O)(=O)C=1C=C2C=CC(Cl)=CC2=CC=1)O)N(CC1)CCC1N1CCCNC1=O GEHAEMCVKDPMKO-HXUWFJFHSA-N 0.000 description 1
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101710112984 20 kDa protein Proteins 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101150011817 KTI3 gene Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 description 1
- 102000003827 Plasma Kallikrein Human genes 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101001045455 Proteus vulgaris Antitoxin HigA Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 101710090398 Viral interleukin-10 homolog Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940087051 fragmin Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 229950010535 razaxaban Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、米国特許法第119条(e)の下で、2012年6月14日に出願された米国仮出願第61/659,821号に対する利益を主張し、その内容は、参照によりその全体が本開示に組み込まれる。
本開示の実施は、別途指示がない限り、従来の組織培養、免疫学、分子生物学、微生物学、細胞生物学、および組み換えDNAの技術を用い、これらは当技術分野の技術の範囲内である。例えば、Sambrook et al.,(1989)Molecular Cloning:A Laboratory Manual,2nd edition、Ausubel et al.,eds.(1987)Current Protocols In Molecular Biology、MacPherson,B.D.Hames and G.R.Taylor eds.,(1995)PCR 2:A Practical Approach、Harlow and Lane,eds.(1988)Antibodies,A Laboratory Manual、Harlow and Lane,eds.(1999)Using Antibodies,a Laboratory Manual、およびR.I.Freshney,ed.(1987)Animal Cell Cultureを参照されたい。
方法
実施例2
ベンズアミジンを含む溶出緩衝液を用いたSTI親和性樹脂によるr−解毒剤の精製
実施例3
アルギニンを含む溶出緩衝液を用いたSTI親和性樹脂によるr−解毒剤の精製
Claims (22)
- セリンプロテアーゼを精製する方法であって、
大豆トリプシンインヒビター(STI)系親和性クロマトグラフに、セリンプロテアーゼを充填することと、
前記STIと前記セリンプロテアーゼとの間の相互作用を妨害する薬剤を含む溶出緩衝液で、前記セリンプロテアーゼを溶出することと、を含む、方法。 - 前記溶出緩衝液が、塩、界面活性剤、および/またはカオトロピック剤を更に含む、請求項1に記載の方法。
- 前記薬剤が、前記セリンプロテアーゼの前記STIに競合的に結合する競合薬である、請求項1または2に記載の方法。
- 前記競合薬が、ベンズアミジン、p−アミノベンズアミジン、アルギニン、小分子fXa阻害剤、ペプチドfXa阻害剤、およびペプチド模倣fXa阻害剤からなる群から選択される、請求項3に記載の方法。
- 前記競合薬がアルギニンである、請求項4に記載の方法。
- 前記セリンプロテアーゼが、配列番号1もしくは2のアミノ酸配列を含むポリペプチドであるか、または、配列番号1もしくは2に対して少なくとも約80%の配列同一性を有し、Glaドメインの少なくとも一部の欠失、および活性部位での変異を有するポリペプチドである、請求項1に記載の方法。
- 前記セリンプロテアーゼが、配列番号2のアミノ酸配列、または、配列番号2に対して少なくとも約95%の配列同一性を有し、前記Glaドメインの少なくとも一部の欠失、および前記活性部位での変異を有するポリペプチドを含む、請求項6に記載の方法。
- 前記セリンプロテアーゼが前記配列番号2のアミノ酸配列を含む、請求項6に記載の方法。
- 前記溶出緩衝液のpHが約4.5〜約10.5である、請求項1〜8のいずれか一項に記載の方法。
- 前記溶出緩衝液の前記pHが約5.0である、請求項9に記載の方法。
- 前記溶出緩衝液の前記pHが約7.4である、請求項9に記載の方法。
- 前記溶出緩衝液が約250mMのアルギニン〜約1000mMのアルギニンを含む、請求項5に記載の方法。
- 前記溶出緩衝液が約500mMのアルギニンを含む、請求項12に記載の方法。
- 前記溶出緩衝液の前記pHが約5.0である、請求項13に記載の方法。
- 前記溶出されたセリンプロテアーゼを、イオン交換カラムでの精製に供することを更に含む、請求項1〜14のいずれか一項に記載の方法。
- 前記セリンプロテアーゼを溶出する前に、塩を含み、中性pHにある洗浄緩衝液で前記クロマトグラフを洗浄することを更に含む、請求項1〜15のいずれか一項に記載の方法。
- 請求項1〜16のいずれか一項に記載の方法によって調製される、精製されたセリンプロテアーゼ。
- キットであって、
大豆トリプシンインヒビター(STI)系親和性クロマトグラフと、
前記STIと前記セリンプロテアーゼとの間の前記相互作用を妨害する競合薬を含む溶出緩衝液と、を含む、キット。 - 前記溶出緩衝液がアルギニンを更に含む、請求項18に記載のキット。
- 前記溶出緩衝液の前記pHが約4.5〜約10.5である、請求項18に記載のキット。
- 前記溶出緩衝液が約250mMのアルギニン〜約1000mMのアルギニンを含む、請求項19に記載のキット。
- 中性pHにある約250mMのNaClを含む洗浄緩衝液を更に含む、請求項18〜21のいずれか一項に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261659821P | 2012-06-14 | 2012-06-14 | |
US61/659,821 | 2012-06-14 | ||
PCT/US2013/045496 WO2013188587A1 (en) | 2012-06-14 | 2013-06-12 | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015521471A true JP2015521471A (ja) | 2015-07-30 |
JP6261093B2 JP6261093B2 (ja) | 2018-01-17 |
Family
ID=48700721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015517406A Active JP6261093B2 (ja) | 2012-06-14 | 2013-06-12 | 組み換え第Xa因子誘導体の精製のための方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20150239929A1 (ja) |
EP (1) | EP2861614B1 (ja) |
JP (1) | JP6261093B2 (ja) |
KR (2) | KR102100629B1 (ja) |
CN (1) | CN104379594B (ja) |
AU (1) | AU2013274288B2 (ja) |
CA (1) | CA2876361C (ja) |
ES (1) | ES2612458T3 (ja) |
HK (1) | HK1209760A1 (ja) |
IL (1) | IL235896B (ja) |
PT (1) | PT2861614T (ja) |
SG (1) | SG11201408028YA (ja) |
WO (1) | WO2013188587A1 (ja) |
ZA (1) | ZA201408921B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018504888A (ja) * | 2014-11-28 | 2018-02-22 | プラトス ナームローズ フェノートサップ | 酵素―阻害剤複合体 |
JP2019528242A (ja) * | 2016-06-17 | 2019-10-10 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第xa因子誘導体の調製 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US20180037604A1 (en) * | 2016-08-04 | 2018-02-08 | Stelis Biopharma Private Limited | Process for the purification of recombinant proteins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62272976A (ja) * | 1985-11-18 | 1987-11-27 | ノバルティス アクチェンゲゼルシャフト | 変異組織プラスミノ−ゲンアクチベ−タ−及びその製造 |
JP2010539945A (ja) * | 2007-09-28 | 2010-12-24 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子阻害剤に対する抗体およびその使用の方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960016514B1 (ko) * | 1990-10-12 | 1996-12-14 | 쿨리건 인터내셔널 컴패니 | 수도꼭지에 설치되는 미생물 필터 |
CN1297896A (zh) * | 1999-11-29 | 2001-06-06 | 中国科学技术大学 | 一种高效提取活化的凝血因子X(FXa)的方法 |
WO2010059232A1 (en) * | 2008-11-20 | 2010-05-27 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
EP3604510A1 (en) * | 2009-03-30 | 2020-02-05 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
WO2010127980A1 (en) | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Fret-based binding assay |
-
2013
- 2013-06-12 KR KR1020147036450A patent/KR102100629B1/ko active IP Right Grant
- 2013-06-12 KR KR1020207010091A patent/KR102210574B1/ko active IP Right Grant
- 2013-06-12 SG SG11201408028YA patent/SG11201408028YA/en unknown
- 2013-06-12 JP JP2015517406A patent/JP6261093B2/ja active Active
- 2013-06-12 CN CN201380033420.3A patent/CN104379594B/zh active Active
- 2013-06-12 EP EP13732317.6A patent/EP2861614B1/en active Active
- 2013-06-12 US US14/406,645 patent/US20150239929A1/en not_active Abandoned
- 2013-06-12 CA CA2876361A patent/CA2876361C/en active Active
- 2013-06-12 PT PT137323176T patent/PT2861614T/pt unknown
- 2013-06-12 AU AU2013274288A patent/AU2013274288B2/en active Active
- 2013-06-12 WO PCT/US2013/045496 patent/WO2013188587A1/en active Application Filing
- 2013-06-12 ES ES13732317.6T patent/ES2612458T3/es active Active
-
2014
- 2014-11-25 IL IL235896A patent/IL235896B/en active IP Right Grant
- 2014-12-04 ZA ZA2014/08921A patent/ZA201408921B/en unknown
-
2015
- 2015-10-20 HK HK15110322.1A patent/HK1209760A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62272976A (ja) * | 1985-11-18 | 1987-11-27 | ノバルティス アクチェンゲゼルシャフト | 変異組織プラスミノ−ゲンアクチベ−タ−及びその製造 |
JP2010539945A (ja) * | 2007-09-28 | 2010-12-24 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子阻害剤に対する抗体およびその使用の方法 |
Non-Patent Citations (2)
Title |
---|
BOCK, P. E. ET AL.: ""Isolation of human blood coagulation alpha-factor Xa by soybean trypsin inhibitor-sepharose chromat", ARCH. BIOCHEM. BIOPHYS., vol. 273, JPN6017019988, 1989, pages 375 - 388, ISSN: 0003568706 * |
CRAIK, C. S. ET AL.: ""Redesigning trypsin: alteration of substrate specificity"", SCIENCE, vol. 228, JPN6017019992, 1985, pages 291 - 297, ISSN: 0003568707 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018504888A (ja) * | 2014-11-28 | 2018-02-22 | プラトス ナームローズ フェノートサップ | 酵素―阻害剤複合体 |
JP2020171293A (ja) * | 2014-11-28 | 2020-10-22 | プラトス ナームローズ フェノートサップ | 酵素組成物 |
US11214783B2 (en) | 2014-11-28 | 2022-01-04 | Puratos Nv | Enzyme-inhibitor complexes comprising a thermostable hydrolase and a temperature sensitive inhibitor |
JP2019528242A (ja) * | 2016-06-17 | 2019-10-10 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第xa因子誘導体の調製 |
JP2022000477A (ja) * | 2016-06-17 | 2022-01-04 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第xa因子誘導体の調製 |
JP7273918B2 (ja) | 2016-06-17 | 2023-05-15 | ポートラ ファーマシューティカルズ, エルエルシー | 第xa因子誘導体の調製 |
Also Published As
Publication number | Publication date |
---|---|
CN104379594A (zh) | 2015-02-25 |
EP2861614A1 (en) | 2015-04-22 |
ES2612458T3 (es) | 2017-05-17 |
SG11201408028YA (en) | 2015-01-29 |
US20150239929A1 (en) | 2015-08-27 |
EP2861614B1 (en) | 2016-11-30 |
AU2013274288A1 (en) | 2015-01-15 |
PT2861614T (pt) | 2017-01-26 |
CA2876361C (en) | 2020-06-30 |
IL235896A0 (en) | 2015-01-29 |
CA2876361A1 (en) | 2013-12-19 |
ZA201408921B (en) | 2020-08-26 |
AU2013274288B2 (en) | 2017-08-17 |
KR102100629B1 (ko) | 2020-04-16 |
KR20150027765A (ko) | 2015-03-12 |
JP6261093B2 (ja) | 2018-01-17 |
WO2013188587A1 (en) | 2013-12-19 |
CN104379594B (zh) | 2017-06-23 |
IL235896B (en) | 2019-02-28 |
KR20200039828A (ko) | 2020-04-16 |
KR102210574B1 (ko) | 2021-02-01 |
HK1209760A1 (en) | 2016-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2698392C2 (ru) | Способ очистки фактора свертывания крови viii | |
JP6261093B2 (ja) | 組み換え第Xa因子誘導体の精製のための方法 | |
JP2022153574A (ja) | 第Xa因子阻害剤に対する抗体およびその使用の方法 | |
EP2453910B1 (en) | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding | |
EP3604510A1 (en) | Antidotes for factor xa inhibitors and methods of using the same | |
JP2019528242A (ja) | 第xa因子誘導体の調製 | |
ES2552337T3 (es) | Procedimientos para la preparación de plasminógeno | |
Rodríguez et al. | Cross-neutralization of the coagulant activity of Crotalus durissus terrificus venom from the northeast of Argentina by bivalent bothropic antivenom | |
JP2022543302A (ja) | 第xa因子及び誘導体を調製するための組成物及び方法 | |
Barkhordari et al. | Direct Cloning, Expression and Purification of Human Activated Thrombin in Prokaryotic System and CD Analysis Report of Produced Thrombin: Molecular Characterization of Recombinant Thrombin | |
AU2015301712B2 (en) | Factor X activation | |
JP6571011B2 (ja) | 陰イオン交換クロマトグラフィーによるビタミンk依存性タンパク質の精製方法 | |
JP2014525475A (ja) | 凝固因子を処理する方法 | |
Amin et al. | Direct Cloning, Expression and Purification of Human Activated Thrombin in Prokaryotic System and CD Analysis Report of Produced Thrombin: Molecular Characterization of Recombinant Thrombin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170831 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6261093 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |